What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Chemotherapy
His scientific interests lie mostly in Internal medicine, Immunology, Oncology, Ibrutinib and Chronic lymphocytic leukemia.
The concepts of his Internal medicine study are interwoven with issues in Gastroenterology and Surgery.
His Immunology research focuses on Disease and how it relates to Biopsy Site, Predictive value of tests, Radiation therapy and Retrospective cohort study.
His study in Oncology is interdisciplinary in nature, drawing from both Monoclonal, Survival rate, Adverse effect and Ofatumumab, Rituximab.
His Ibrutinib research includes elements of Progressive disease, Lymphocytosis and Bruton's tyrosine kinase.
His studies in Chronic lymphocytic leukemia integrate themes in fields like Cancer research and Kinase.
His most cited work include:
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia (1539 citations)
- Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. (1170 citations)
- Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. (991 citations)
What are the main themes of his work throughout his whole career to date?
Richard R. Furman mostly deals with Internal medicine, Chronic lymphocytic leukemia, Oncology, Immunology and Ibrutinib.
His Internal medicine research includes themes of Gastroenterology and Surgery.
The study incorporates disciplines such as Cancer research and Bruton's tyrosine kinase in addition to Chronic lymphocytic leukemia.
His Oncology research is multidisciplinary, incorporating elements of Clinical trial, Chemotherapy, Refractory and Lymphoma.
His study in Immunology focuses on CD20 in particular.
His research in Ibrutinib intersects with topics in Progressive disease, Discontinuation, Chemoimmunotherapy, Venetoclax and Lymphocytosis.
He most often published in these fields:
- Internal medicine (64.48%)
- Chronic lymphocytic leukemia (35.77%)
- Oncology (30.73%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (64.48%)
- Chronic lymphocytic leukemia (35.77%)
- Oncology (30.73%)
In recent papers he was focusing on the following fields of study:
Richard R. Furman mainly focuses on Internal medicine, Chronic lymphocytic leukemia, Oncology, Ibrutinib and Cancer research.
Richard R. Furman frequently studies issues relating to Gastroenterology and Internal medicine.
The study incorporates disciplines such as Cancer and Clinical trial in addition to Chronic lymphocytic leukemia.
His Oncology research is multidisciplinary, incorporating perspectives in Richter's transformation, Fludarabine and Ofatumumab, Rituximab.
Richard R. Furman works mostly in the field of Ibrutinib, limiting it down to topics relating to Survival rate and, in certain cases, [email protected]
His Cancer research study also includes fields such as
- Mantle cell lymphoma that intertwine with fields like Lenalidomide and Diffuse large B-cell lymphoma,
- PI3K/AKT/mTOR pathway which intersects with area such as Duvelisib.
Between 2017 and 2021, his most popular works were:
- Single-Agent Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia: A 5-Year Experience (201 citations)
- Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. (158 citations)
- Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL (132 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Gene
Richard R. Furman mainly investigates Internal medicine, Ibrutinib, Neutropenia, Chronic lymphocytic leukemia and Gastroenterology.
His Internal medicine study frequently draws connections between adjacent fields such as Oncology.
The Ibrutinib study combines topics in areas such as Chemotherapy, Survival rate, Retrospective cohort study, Rituximab and Cohort.
His Neutropenia study combines topics from a wide range of disciplines, such as Waldenstrom macroglobulinemia, Phases of clinical research, Tolerability, Clinical endpoint and Acalabrutinib.
His biological study deals with issues like Refractory, which deal with fields such as Tyrosine-kinase inhibitor.
The concepts of his Gastroenterology study are interwoven with issues in International Prognostic Index and Minimal residual disease.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
